Imricor Medical Systems Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Steve Wedan

Chief Executive Officer (CEO)

US$464.9k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	18yrs
Participación del CEO	2.5%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Wedan en comparación con los beneficios de Imricor Medical Systems?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$465k	US$465k	-US$23m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$465k	US$465k	-US$17m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$20m
Dec 31 2021	US$577k	US$464k	-US$20m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$565k	US$452k	-US$12m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$349k	US$349k	-US$13m

Compensación vs. Mercado: La compensación total de Steve($USD464.90K) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD289.12K).

Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.

CEO

Steve Wedan (54 yo)

18yrs

Permanencia

US$464,900

Compensación

Mr. Steve Wedan has been the Chief Executive Officer, President and Director of Imricor Medical Systems Inc. since May 23, 2006 and serves as its Executive Chairman. Mr. Wedan has medical device experience...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Steve Wedan	President	18yrs	US$464.90k	2.46% $ 2.2m
Jonathon Gut	CFO & VP of Finance	1.8yrs	US$259.38k	sin datos
Gregg Stenzel	Chief Operating Officer	17.3yrs	US$315.00k	sin datos
Greg Englehardt	Senior Director of Sales	6.3yrs	sin datos	sin datos
Nick Twohy	Vice President of Marketing & Business Development	5.3yrs	sin datos	sin datos
Kobe Lizheng	Company Secretary & Local Agent	5.1yrs	sin datos	sin datos

5.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de IMR es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steve Wedan	President	18yrs	US$464.90k	2.46% $ 2.2m
Anita Messal	Independent Non-Executive Director	3.2yrs	US$75.00k	0.12% $ 112.5k
Peter McGregor	Independent Non-Executive Director	5yrs	US$80.00k	0.38% $ 341.2k
Mark Tibbles	Independent Deputy Chairman & Lead Independent Director	9.7yrs	US$80.00k	3.02% $ 2.7m

7.3yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de IMR se considera experimentada (7.3 años de antigüedad promedio).

Imricor Medical Systems Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Non-Executive Director recently bought AU$73k worth of stock

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Insufficient new directors

Key Executive recently bought AU$195k worth of stock

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Recent updates

Independent Non-Executive Director recently bought AU$73k worth of stock

Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million.

Insufficient new directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022)

Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million.

First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022)

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding

Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023

Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding

New minor risk - Share price stability

Key Executive recently bought AU$195k worth of stock

Full year 2022 earnings released

Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023

Imricor Medical Systems, Inc. Receives IDE Approval from US FDA

Forecast to breakeven in 2025

Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial

Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial

Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding

First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021)

Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022

Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022

Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe

Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Imricor Medical Systems, Inc. Announces Executive Changes

Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration

First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020)

No longer forecast to breakeven

Non-Executive Director has left the company

Imricor Medical Systems, Inc. Announces Board Changes

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019)

Revenue beats expectations

New 90-day low: AU$2.17

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Imricor Medical Systems, Inc. Appoints Gregg Stenzel as COO

Imricor Signs Supply and Sales Agreement with Osypka

Imricor Medical Systems, Inc. Signs New Purchase Agreement

Imricor Medical Systems, Inc. (ASX:IMR) signed an agreement to acquire Schleswig-Holstein University Medical Centre in Germany.

Imricor Medical Systems, Inc. to Commence Clinical Procedures After Receiving Ethics Committee Approval to Use Isuite Software

Imricor Awards National Institutes of Health Contract

Imricor Medical Systems, Inc. Signs Purchase Agreement with MUMC

Leipzig Heart Centre Signs Purchase Agreement with Imricor Medical Systems

Earnings released

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Aug 25, 2020

Imricor Medical Systems, Inc. to Report Q2, 2020 Results on Jul 29, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad